The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 06, 2017
Filed:
Sep. 15, 2011
Jude O'donnell, Galbally, GB;
Max Bylesjo, Glasgow, GB;
Fionnuala Patterson, Greenisland, GB;
Steve Deharo, Hillsborough, GB;
Laura A. Hill, Lisburn, GB;
Katherine E. Keating, Magherafelt, GB;
Timothy Davison, Hillsborough, GB;
Vitali Proutski, Hillsborough, GB;
Denis Paul Harkin, Dromore, GB;
Richard Kennedy, Belfast, GB;
Nicolas Goffard, Belfast, GB;
Jude O'Donnell, Galbally, GB;
Max Bylesjo, Glasgow, GB;
Fionnuala Patterson, Greenisland, GB;
Steve Deharo, Hillsborough, GB;
Laura A. Hill, Lisburn, GB;
Katherine E. Keating, Magherafelt, GB;
Timothy Davison, Hillsborough, GB;
Vitali Proutski, Hillsborough, GB;
Denis Paul Harkin, Dromore, GB;
Richard Kennedy, Belfast, GB;
Nicolas Goffard, Belfast, GB;
ALMAC DIAGNOSTICS LIMITED, , GB;
Abstract
Methods and compositions are provided for the identification of a molecular diagnostic test for cancer. The test defines a novel DNA damage repair deficient molecular subtype and enables classification of a patient within this subtype. The present invention can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to administration of any chemotherapy. This test may be used in different cancer types and with different drugs that directly or indirectly affect DNA damage or repair, such as many of the standard cytotoxic chemotherapeutic drugs currently in use. In particular, the present invention is directed to the use of certain combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen.